Table of Contents Author Guidelines Submit a Manuscript
Journal of Spectroscopy
Volume 2013, Article ID 593636, 6 pages
http://dx.doi.org/10.1155/2013/593636
Research Article

Preparation and Characterization of Lanthanum Carbonate Octahydrate for the Treatment of Hyperphosphatemia

1College of Chemistry and Molecular Engineering, Peking University, Beijing 100871, China
2School of Materials Science and Technology, China University of Geosciences, Beijing 100083, China
3Beijing Coway Pharm. Co. Ltd., Beijing 100094, China
4School of Medicine, Henan University, Kaifeng 471003, China
5Tianjin Cenway Pharm. Co. Ltd., Tianjin 300480, China
6College of Pharmacy, Liaoning University of Traditional Chinese Medicine, Shenyang 11660, China
7College of Chemistry and Material Science, Hebei Normal University, Shijiazhuang 050024, China

Received 6 September 2013; Accepted 15 October 2013

Academic Editor: Isao Noda

Copyright © 2013 Anqi He et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Albaaj and A. J. Hutchison, “Hyperphosphataemia in renal failure: causes, consequences and current management,” Drugs, vol. 63, no. 6, pp. 577–596, 2003. View at Publisher · View at Google Scholar · View at Scopus
  2. T. Plagemann, A. Prenzler, and T. Mittendorf, “Considerations about the effectiveness and cost effectiveness of therapies in the treatment of hyperphosphataemia,” Health Economics Review, vol. 1, no. 1, pp. 1–9, 2011. View at Google Scholar
  3. J. J. Schucker and K. E. Ward, “Hyperphosphatemia and phosphate binders,” American Journal of Health-System Pharmacy, vol. 62, no. 22, pp. 2355–2361, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. D. D. Freitas, R. L. Donne, and A. J. Hutchison, “Lanthanum carbonate—a first line phosphate binder?” Current Opinion in Nephrology & Hypertension, vol. 13, no. 6, pp. 403–409, 2004. View at Google Scholar
  5. J. A. Coladonato, “Control of hyperphosphatemia among patients with ESRD,” Journal of the American Society of Nephrology, vol. 16, no. 11, pp. S107–S114, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Tonelli, N. Pannu, and B. Manns, “Oral phosphate binders in patients with kidney failure,” New England Journal of Medicine, vol. 362, no. 14, pp. 1212–1324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. H. H. Malluche and H. Mawad, “Management of hyperphosphataemia of chronic kidney disease: lessons from the past and future directions,” Nephrology Dialysis Transplantation, vol. 17, no. 7, pp. 1170–1175, 2002. View at Google Scholar · View at Scopus
  8. S. P. Fricker, “The therapeutic application of lanthanides,” Chemical Society Reviews, vol. 35, no. 6, pp. 524–533, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. B. A. Murrer and N. A. Powell, “Pharmaceutical composition containing selected lanthanum carbonate hydrates,” Patent US 5968976, 1999.
  10. B. A. Murrey and N. A. Powell, “Pharmaceutical composition containing selected lanthanum carbonate hydrates,” Patent CN 96193918.4, 1996.
  11. P. Jeevanandam, Y. Koltypin, O. Palchik, and A. Gedanken, “Synthesis of morphologically controlled lanthanum carbonate particles using ultrasound irradiation,” Journal of Materials Chemistry, vol. 11, no. 3, pp. 869–873, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. J. C. Ferdinando and D. Gilmour, “Method of treating hyperphosphataemia using lanthanum hydroxyl carbonate,” Patent CN 200580030985.1, 27 7 2005.